Earnings call transcript: Alicorp Q1 2026 sees earnings beat, stock up 4.83%

Alicorp delivered a modest Q1 2026 beat, with EPS of $0.29 versus $0.2815 expected, a 3.02% surprise, while revenue reached $2.93B and the stock rose 4.83% to $11.50. Adjusted gross profit increased 5.4% to PEN 791M and adjusted EBITDA rose 5.5% to PEN 459M, supported by 12.5% sales volume growth in Consumer Goods Peru and contributions from recent acquisitions. Management reaffirmed full-year 2026 guidance for low-to-mid single-digit revenue and EBITDA growth, but flagged FX, inflation, supply chain, and Bolivia macro volatility as ongoing risks.

Analysis

The real signal here is not the beat itself; it’s that management is choosing to spend incremental gross profit on brand investment while still defending EBITDA growth. That tells us they likely see pricing power and share gains as more durable than the market is giving credit for, especially in Peru where volume-led share wins can compound for multiple quarters before showing up in margin. In other words, the quarter is a proof point that near-term earnings can be reinvested into a longer-duration moat rather than harvested for short-term margin expansion.

The second-order issue is capital allocation risk. The company is layering M&A on top of a still-elevated leverage profile, and the stated guidance implies debt metrics can temporarily move higher if the pending transactions close; that creates an asymmetry where the equity benefits immediately from consolidation but can be punished later if integration drags or FX turns against them. The market is likely underweighting how much the international and B2B businesses are exposed to commodity/weather-linked volatility, which can obscure underlying consumer strength and create intermittent drawdowns even if the core franchise remains intact.

Contrarian view: the stock may not be as cheap as headline multiples suggest once you normalize for acquisition-driven earnings and the cost of keeping growth elevated. The cleanest tell is the management answer on margins outside Peru: they are signaling stability first, expansion later, which implies 2026 is more of a digestion year than a re-acceleration year. That argues for trading the setup as a quality compounder with event risk, not a straight valuation re-rating story.

Key Decisions for Investors

• Go long ALICORC1 on pullbacks over the next 1-3 weeks; target a 6-10% re-rating if the market starts underwriting the acquisition-driven mix shift, but size modestly because leverage and FX remain the main disconfirming risks.
• Use a call spread in ALICORC1 for 3-6 months rather than stock if available liquidity permits; the upside is tied to integration success and category expansion, while downside is capped by macro/FX noise and deal timing.
• Pair trade: long ALICORC1 / short a more levered EM consumer staple with weaker brand equity and higher FX sensitivity over 1-2 quarters; this isolates execution quality and acquisition optionality from broad EM risk.
• If ALICORC1 rallies into the top end of its 52-week range before Flora visibility improves, trim 25-33% and wait for confirmation on regulatory progress; the market will likely pay for optionality early but punish slippage hard.
• Avoid chasing pure equity upside in the B2B/LatAm exposure until there is evidence palm availability and Bolivia FX pressure are stabilizing; the better risk/reward is through event-driven upside, not open-ended macro exposure.